Delivery Order SPE2DB22D3010-SPE2DB25FP1VR

Award Date 3/7/25
Potential Completion Date 3/10/25
Potential Value $8.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was granted by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order valued at $4,733.59 for the supply of 4,566,262,385 units of Ondansetron HCL 8 mg tablets. The contract has an ultimate completion date of October 30, 2024 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $48,748.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,563,250,472 units of the drug Ondansetron ODT 4 mg tablet, with a performance period through January 8, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
This federal contract award, valued at $7,593.20, was issued by the Defense Logistics Agency's (DLA) Troop Support Medical division to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Ondansetron HCl 8 mg tablets and is a firm fixed-price delivery order. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $28,999.00, is a Delivery Order for the supply of 4,566,304,145 units of Ondansetron HCL 4 mg Tablets. This Firm Fixed Price contract has an ultimate completion date of November 4, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,011.88 firm-fixed-price delivery order is for the supply of 4 mg Ondansetron HCL tablets. The contract has an ultimate completion date of July 22, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award to Amerisourcebergen Drug Corp, valued at $5,546.18, was issued by the Defense Logistics Agency (DLA) to provide 4,567,090,949 units of Ondansetron HCL 4 mg tablets. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for the company to supply a comprehensive range of pharmaceutical products and medical supplies to...
The U.S. Defense Logistics Agency (DLA) awarded a $14,550.99 firm-fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office division. The order is for the supply of 4,564,299,405 units of the pharmaceutical product Ondansetron ODT 8 mg Tablets. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025. The IDC enables DLA to efficiently procure essential...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $22,277.07, is for the delivery of 4,564,792,273 units of the medication Ondansetron HCL 4 mg tablets. The contract is a Firm Fixed Price Delivery Order with a completion date of June 4, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award, valued at $4,555.91, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of 4,566,148,838 units of Ondansetron HCL 4 mg Tablets in 30-count packages. The award has an ultimate completion date of October 21, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,249.02 firm fixed-price delivery order contract is for the provision of 4,567,155,720 units of Ondansetron ODT 8 mg tablets. This contract award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle...
  • SPE2DB22D3010
    Indefinite Delivery Contract
  • SPE2DB22D3010-SPE2DB25FP1VR
    Delivery Order

This federal contract award, valued at $8,540.16, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a Delivery Order under an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, covers the delivery of 4,567,500 units of the medication Ondansetron HCL 4 mg Tablet. The IDC, valued at $999,999,999 and running through November 2026, serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific award does not have a set-aside designation, indicating open competition. AmerisourceBergen's extensive experience and capabilities in the federal healthcare supply chain make it a key vendor for the DLA and other government agencies.

Generated 6/6/25, 9:58 AM